Cost of New PCSK9 Inhibitors May Overwhelm Patients and Payers

A new class of injectable cholesterol-lowering drugs, PCSK9 inhibitors, are good news for patients who are unresponsive to statins, but their current price. How will payers make this work? Read more here. (Source: Tracey Walker, Managed Healthcare Executive, 9/2/15)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… 07/22/2019
Biomarkers and Companion diagnostics: Payer Insights 09/26/2019
ICER Releases Final Report for Type 2 Diabetes Add-on Therapies 12/10/2019
The Future of Personalised Medicine: The Role of Simulation… 01/25/2020
ISMPP Poll: How Would You Handle an Unresponsive Lead Author? 11/01/2019
Leveraging Technology to Reduce Costs in Clinical Trials 06/30/2019
The Global Use of Medicine in 2019 and Outlook to 2023 01/29/2019